SEQUIVITY™ RNA PARTICLE TECHNOLOGY

OUR PROCESS Gene of Interest = GOI
RNA Particles = RPs

1. A sample is collected and sent to the lab by a veterinarian.



2. GOI is identified and sent electronically.

3. GOI is synthesized and inserted into the RNA production platform.

4. After incubation, RNA particles released from the production cells are harvested, purified and formulated into a final vaccine.

Revolutionizing vaccine production

In a world where diseases evolve and mutate continuously, Merck Animal Health is making sure producers can address their animals' health with strain-specific vaccines through SEQUIVITY RNA Particle Technology. This new way to approach vaccine production offers a safe and innovative solution to today's herd health challenges.

PRECISE

SEQUIVITY RNA Particle Technology takes a genetic sequence from a targeted pathogen, isolated from an infected animal, to create a herd-specific vaccine in a matter of weeks.

SAFE

The RNA particles are designed to just deliver information to the immune system and not to replicate, so they can't cause disease. And because just an electronic gene sequence enters our production facilities, biosecurity is maximized.

FLEXIBLE

SEQUIVITY RNA Particle Technology lets producers and veterinarians target multiple pathogens and farm-specific strains with a single injection.

SEQUIVITY™

Biologicals of the future – Available today

When herd health management requires the most advanced, tailored vaccination solutions – look to SEQUIVITY RNA Particle Technology from Merck Animal Health.

merck-animal-health-usa.com 800-521-5767

©2018 Intervet Inc., doing business as Merck Animal Health, a subsidiary of Merck & Co., All rights reserved.

MERCK Animal Health